Alignment Healthcare

ALHC · NASDAQ

$8.51+$0.11 (+1.31%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.40

ALHC analyst rating

BuyConsensus of 10 analysts over the last 12 months. 60% rate it a buy.

Strong buy0
Buy6
Hold4
Underperform0
Sell0

12-month price target · 15 analysts

Average $22.69 (+166.7% upside)

Low: $13.13
Now: $8.51
High: $29.40

Upgrades and downgrades

The latest rating actions, newest first

ALHC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Maintains	Neutral	$22.00 → $9.00	60%
TD Cowen	Oct 12, 2026	Maintains	Buy	$21.00 → $12.00	67%
William Blair	Oct 9, 2026	Downgrade	Outperform → Market Perform	—	15%
JP Morgan	Oct 9, 2026	Maintains	Overweight	$22.00 → $10.00	60%
Keybanc	Oct 9, 2026	Maintains	Overweight	$28.00 → $12.00	61%
Barclays	Oct 6, 2026	Maintains	Equal-Weight	$16.00 → $10.00	59%
JP Morgan	Aug 4, 2026	Maintains	Overweight	$26.00 → $22.00	60%
Raymond James	Aug 3, 2026	Downgrade	Strong Buy → Outperform	$22.00 → $19.00	65%
Barclays	May 26, 2026	Maintains	Equal-Weight	$19.00 → $16.00	59%
UBS	May 1, 2026	Maintains	Neutral	$21.00 → $22.00	60%

The case for and against

Updated Feb 9, 2026

Bull case

Alignment Healthcare Inc is strategically positioned to leverage the anticipated favorable 2026 rate update, especially as many managed care organizations are reducing benefits, granting ALHC a competitive edge through its Stars funding advantage. The company's integrated Medicare Advantage value-based care model is expected to foster long-term market share gains and above-average growth, supported by promising gross profit per member per month metrics projected to improve from $90-$150 in the first two years to over $230 in years three to five. Additionally, the stronger-than-expected 2026 MA rate update may enhance membership growth and improve cohort margin maturation, further contributing to the company's positive financial outlook.

Bear case

Alignment Healthcare Inc faces challenges that contribute to a negative outlook, primarily due to data friction across different payors and inconsistent outcomes from employed or affiliated primary care providers (PCPs). While the company has reported lower average daily costs (ADK) amidst increased healthcare utilization, the implications of the rising costs and complexities related to the Medicare Advantage market can strain financial performance. Additionally, despite the company’s above-average EBITDA growth relative to peers, its valuation multiple remains slightly elevated, suggesting that potential risks may not be fully reflected in the stock price.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.